RNA demethylase ALKBH5 promotes ovarian carcinogenesis in a simulated tumour microenvironment through stimulating NF-κB pathway.


Journal

Journal of cellular and molecular medicine
ISSN: 1582-4934
Titre abrégé: J Cell Mol Med
Pays: England
ID NLM: 101083777

Informations de publication

Date de publication:
06 2020
Historique:
received: 26 05 2019
revised: 23 12 2019
accepted: 01 03 2020
pubmed: 25 4 2020
medline: 29 4 2021
entrez: 25 4 2020
Statut: ppublish

Résumé

Methylation is the main form of RNA modification. N6-methyladenine (m6A) regulates the splicing and translation of mRNA. Alk B homologue 5 (ALKBH5) participates in the biological regulation of various cancers. However, its role in ovarian carcinogenesis has not been unveiled. In the present study, ALKBH5 showed higher expression in ovarian cancer tissue than in normal ovarian tissue, but lower expression in ovarian cancer cell lines than in normal ovarian cell lines. Interestingly, Toll-like receptor (TLR4), a molecular functioning in tumour microenvironment (TME), demonstrated the same expression trend. To investigate the effect of abnormal TME on ovarian carcinogenesis, we established an in vitro model in which macrophages and ovarian cancer cells were co-cultured. In the ovarian cancer cells co-cultured with M2 macrophages, the expression of ALKBH5 and TLR4 increased. We also verified that TLR4 up-regulated ALKBH5 expression via activating NF-κB pathway. Depending on transcriptome sequencing, m6A-Seq and m6A MeRIP, we found that NANOG served as a target in ALKBH5-mediated m6A modification. NANOG expression increased after mRNA demethylation, consequently enhancing the aggressiveness of ovarian cancer cells. In conclusion, highly expressed TLR4 activated NF-κB pathway, up-regulated ALKBH5 expression and increased m6A level and NANOG expression, all contributing to ovarian carcinogenesis. Our study revealed the role of m6A in ovarian carcinogenesis, providing a clue for inventing new target therapy.

Identifiants

pubmed: 32329191
doi: 10.1111/jcmm.15228
pmc: PMC7294121
doi:

Substances chimiques

NF-kappa B 0
Nanog Homeobox Protein 0
Toll-Like Receptor 4 0
AlkB Homolog 5, RNA Demethylase EC 1.14.11.-
Alpha-Ketoglutarate-Dependent Dioxygenase FTO EC 1.14.11.33
FTO protein, human EC 1.14.11.33

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

6137-6148

Informations de copyright

© 2020 The Authors. Journal of Cellular and Molecular Medicine published by Foundation for Cellular and Molecular Medicine and John Wiley & Sons Ltd.

Références

J Funct Biomater. 2015 Feb 17;6(1):81-103
pubmed: 25695337
J Biol Chem. 2014 Jun 20;289(25):17299-311
pubmed: 24778178
Cell. 2011 Mar 4;144(5):646-74
pubmed: 21376230
Anal Biochem. 1976 May 7;72:248-54
pubmed: 942051
Nat Rev Genet. 2014 May;15(5):293-306
pubmed: 24662220
Cancer Res. 2006 Apr 1;66(7):3859-68
pubmed: 16585214
J Mol Biol. 1977 Oct 5;115(4):695-714
pubmed: 592376
Cancer Lett. 2018 Oct 1;433:242-251
pubmed: 29964205
World J Surg Oncol. 2012 Sep 17;10:193
pubmed: 22985132
Tumour Biol. 2016 Oct;37(10):13279-13286
pubmed: 27460076
Nat Cell Biol. 2014 Feb;16(2):191-8
pubmed: 24394384
Cell. 2010 Mar 19;140(6):883-99
pubmed: 20303878
Nature. 2014 Jan 2;505(7481):117-20
pubmed: 24284625
Semin Cancer Biol. 2018 Aug;51:160-169
pubmed: 28782606
J Transl Med. 2013 Jun 13;11:147
pubmed: 23763830
Nat Rev Mol Cell Biol. 2014 May;15(5):313-26
pubmed: 24713629
JAMA Oncol. 2019 Jan 1;5(1):51-57
pubmed: 30128536
J Mol Biol. 1979 Dec 15;135(3):733-52
pubmed: 537090
Cell. 2015 Jun 4;161(6):1388-99
pubmed: 26046440
Nucleic Acids Res. 1983 Mar 11;11(5):1475-89
pubmed: 6828386
Cytokine. 2012 May;58(2):133-47
pubmed: 22349527
Pathobiology. 2013;80(3):146-54
pubmed: 23364389
BMC Genomics. 2003 Dec 10;4(1):48
pubmed: 14667252
CA Cancer J Clin. 2018 Jan;68(1):7-30
pubmed: 29313949
J Transl Med. 2012 Apr 25;10:77
pubmed: 22533866
Nat Rev Cancer. 2009 Jan;9(1):57-63
pubmed: 19052556
Nat Genet. 2018 Sep;50(9):1262-1270
pubmed: 30104763
Cell Res. 2014 Feb;24(2):177-89
pubmed: 24407421
Oncotarget. 2016 Oct 4;7(40):64527-64542
pubmed: 27590511
Nat Chem Biol. 2014 Feb;10(2):93-5
pubmed: 24316715
Cancer Cell. 2017 Apr 10;31(4):591-606.e6
pubmed: 28344040
Mol Cancer. 2018 Jul 31;17(1):109
pubmed: 30064416
Mol Cell Biol. 1988 Jun;8(6):2280-7
pubmed: 3405205
Nature. 2012 Apr 29;485(7397):201-6
pubmed: 22575960
Breast Cancer Res. 2009;11(1):R7
pubmed: 19187537
Mol Cell. 2013 Jan 10;49(1):18-29
pubmed: 23177736
Oncotarget. 2018 Feb 21;9(29):20908-20927
pubmed: 29755698
Biotechniques. 1995 Aug;19(2):192-5
pubmed: 8527134
Target Oncol. 2018 Oct;13(5):583-598
pubmed: 30229471
Oncogene. 2009 Dec 10;28(49):4353-63
pubmed: 19826413
J Cell Mol Med. 2020 Jun;24(11):6137-6148
pubmed: 32329191

Auteurs

Yi Jiang (Y)

Department of Gynecology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.

Yicong Wan (Y)

Department of Gynecology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.

Mi Gong (M)

Department of Gynecology, The Affiliated Huai'an No.1 People's Hospital of Nanjing Medical University, Huai'an, China.

Shulin Zhou (S)

Department of Gynecology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.

Jiangnan Qiu (J)

Department of Gynecology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.

Wenjun Cheng (W)

Department of Gynecology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH